(Q33607634)

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

A pilot clinical trial of a new oral hypoglycemic agent, CS-045, in patients with non-insulin dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Effects of a new oral hypoglycaemic agent (CS-045) on metabolic abnormalities and insulin resistance in type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus. A randomized, double-blind, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Mortality and survival in type 2 (non-insulin-dependent) diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Impaired glucose tolerance is normalized by treatment with the thiazolidinedione troglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Long-term complications of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Effects of Troglitazone (CS-045) on insulin secretion in isolated rat pancreatic islets and HIT cells: an insulinotropic mechanism distinct from glibenclamide

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

A novel antidiabetic drug, troglitazone--reason for hope and concern.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Prevention and treatment of the complications of diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Troglitazone-induced hepatic failure leading to liver transplantation. A case report

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Effect of troglitazone on insulin sensitivity and pancreatic beta-cell function in women at high risk for NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

PPAR-gamma: adipogenic regulator and thiazolidinedione receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Activators of the nuclear receptor PPARgamma enhance colon polyp formation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Reduction of Insulin Resistance in Obese and/or Diabetic Animals by 5-[4-(1-Methylcyclohexylmethoxy)benzyl]-thiazolidine-2,4-dione (ADD-3878, U-63,287, Ciglitazone), a New Antidiabetic Agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Characterization of new oral antidiabetic agent CS-045. Studies in KK and ob/ob mice and Zucker fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

21 January 2018

Sulfonylureas in NIDDM.

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

A new antidiabetic agent, BRL 49653, reduces lipid availability and improves insulin action and glucoregulation in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Ciglitazone, a new hypoglycaemic agent. 3. Effect on glucose disposal and gluconeogenesis in vivo in C57BL/6J-ob/ob and -+/? mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Ciglitazone, a New Hypoglycemic Agent: I. Studies in ob/ob and db/db Mice, Diabetic Chinese Hamsters, and Normal and Streptozotocin-Diabetic Rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Actions of novel antidiabetic agent englitazone in hyperglycemic hyperinsulinemic ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

The effect of CP 68,722, a thiozolidinedione derivative, on insulin sensitivity in lean and obese Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Repeat treatment of obese mice with BRL 49653, a new potent insulin sensitizer, enhances insulin action in white adipocytes. Association with increased insulin binding and cell-surface GLUT4 as measured by photoaffinity labeling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Metabolic effects of troglitazone on fat-induced insulin resistance in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Metabolic effects of troglitazone in the Goto-Kakizaki rat, a non-obese and normolipidemic rodent model of non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Acute effects of troglitazone on in vivo insulin action in normal rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

The efficacy of acarbose in the treatment of patients with non-insulin-dependent diabetes mellitus. A multicenter controlled clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Troglitazone action is independent of adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Antihypertensive effects of CS-045 treatment in obese Zucker rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Increased feeding in fatty Zucker rats by the thiazolidinedione BRL 49653 (rosiglitazone) and the possible involvement of leptin and hypothalamic neuropeptide Y.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Thiazolidinediones repress ob gene expression in rodents via activation of peroxisome proliferator-activated receptor gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Effects of ciglitazone on blood pressure and intracellular calcium metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels, and lowers blood pressure, in obese, insulin-resistant rhesus monkeys.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Attenuation of hypertension by insulin-sensitizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Long-term efficacy and safety of acarbose in the treatment of obese subjects with non-insulin-dependent diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Thiazolidinediones in the treatment of insulin resistance and type II diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Fatty acids and retinoids control lipid metabolism through activation of peroxisome proliferator-activated receptor-retinoid X receptor heterodimers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Peroxisome proliferator-activated receptors: a nuclear receptor signaling pathway in lipid physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Sulfated glycans stimulate endocytosis of the cellular isoform of the prion protein, PrPC, in cultured cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

A human peroxisome-proliferator-activated receptor-gamma is activated by inducers of adipogenesis, including thiazolidinedione drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Transdifferentiation of myoblasts by the adipogenic transcription factors PPAR gamma and C/EBP alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Thiazolidinediones and fatty acids convert myogenic cells into adipose-like cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Treatment of NIDDM with insulin agonists or substitutes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Acute non-insulin-like stimulation of rat muscle glucose metabolism by troglitazone in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Actions of the novel antidiabetic agent englitazone in rat hepatocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

In vitro studies on the action of CS-045, a new antidiabetic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Regulation of glucose transport in cultured muscle cells by novel hypoglycemic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Acute and chronic effects of troglitazone (CS-045) on isolated rat ventricular cardiomyocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Pioglitazone Increases Insulin Sensitivity by Activating Insulin Receptor Kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Troglitazone prevents glucose-induced insulin resistance of insulin receptor in rat-1 fibroblasts

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Thiazolidine derivatives ameliorate high glucose-induced insulin resistance via the normalization of protein-tyrosine phosphatase activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Dietary fats and insulin action

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Troglitazone, an insulin action enhancer, improves metabolic control in NIDDM patients. Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

New oral thiazolidinedione antidiabetic agents act as insulin sensitizers

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Effects of thiazolidinediones on glucocorticoid-induced insulin resistance and GLUT4 glucose transporter expression in rat skeletal muscle.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Glucose transport deficiency in diabetic animals is corrected by treatment with the oral antihyperglycemic agent pioglitazone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

TNF-alpha-induced insulin resistance in vivo and its prevention by troglitazone

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

BRL 49653 blocks the lipolytic actions of tumor necrosis factor-alpha: a potential new insulin-sensitizing mechanism for thiazolidinediones

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Antidiabetic thiazolidinediones inhibit leptin (ob) gene expression in 3T3-L1 adipocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Effect of troglitazone on leptin production. Studies in vitro and in human subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Biguanides and sulfonylureas as combination therapy in NIDDM.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Effect of combination therapy of troglitazone and sulphonylureas in patients with Type 2 diabetes who were poorly controlled by sulphonylurea therapy alone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Cardiac and glycemic benefits of troglitazone treatment in NIDDM. The Troglitazone Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X

Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1464-5491.1999.00023.X